A Delhi High Court ruling favors Natco Pharma against Roche's rare disease drug. Natco can now launch generic risdiplam, used for spinal mu...

The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...

Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche ...

The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...

Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...

In what could ease access to some patented medicines, the government has allowed global tenders to be floated for procurement of 120 drugs,...

The recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, sa...

Cure SMA Foundation of India, a parent-led organisation, had approached the court seeking exemption of GST and customs duty on treatment of...

The rare disease affects one in every 8,000 children. The bigger problem, according to parents and doctors, is the lack of awareness about ...

Since its launch, over 4,000 SMA patients across over 50 countries have benefitted from the drug, Roche said in a statement.